Medication reconciliation for pediatric oncology patientparticipants enrolled in clinical trials often reveals the use of chemical complementary medicine alongside protocol therapeutic agents. Considering the blurry delineation between clinical ethics and research ethics, this paper demonstrates how complementary medicine-related protocol violations introduce ethical questions of who should be included and excluded from clinical trials and offers recommendations on how to manage physician-patient-family interactions around these challenging issues.
Get full access to this article
View all access options for this article.
References
1.
* Patient information is based on fact, but details have been changed to protect identities.
2.
A. J.Rose, S. H.Fischer, and M. K.Paasche-Orlow, “Beyond Medication Reconciliation: The Correct Medication List,”JAMA317, no. 20 (2017): 2057-2058.
3.
See Rose et al., supra note 1.
4.
J. L.Greenwald, L.Halasylamani, J.Greene, C.LaCivita, E.Stucky, B.Benjamin, W.Reid, F. A.Griffin, A. J.Vaida, and M. V.Williams, “Making Inpatient Medication Reconciliation Patient Centered, Clinically Relevant and Implementable: A Consensus Statement on Key Principles and Necessary First Steps,”Journal of Hospital Medicine5, no. 8 (2010): 477-485; Joint Commission National Patient Safety Goals, January 2017, available at <https://www.jointcommission.org/standards_information/npsgs.aspx>, (last accessed September 14, 2017).
5.
See Rose et al., supra note 1.
6.
F. L.Bishop, P.Prescott, Y. K.Chan, J.Saville, E.von Elm, and G. T.Lewith, “Prevalence of Complementary Medicine Use in Pediatric Cancer: A Systematic Review,”Pediatrics125, no. 4 (2010): 768-776; C. Diorio, K. Salena, E. J. Ladas, C. G. Lam, G. M. Afungcwhi, F. Njuguna, and S. Marjerrison, “Traditional and Complementary Medicine Used with Curative Intent in Childhood Cancer: A Systematic Review,” Pediatric Blood and Cancer 64, no. 9 (2017); T. Magi, C. E. Kuehni, L. Torchetti, L. Wengenroth, S. Lüer, and M. Frei-Erb, “Use of Complementary and Alternative Medicine in Children with Cancer: A Study at a Swiss University Hospital,” PLoS ONE 10, no. 12 (2015); M. A. Paisley, T. I. Kang, I. G. Isogna, and S. R. Rheingold, “Complementary Therapy Use in Pediatric Oncology Patients with Failure of Frontline Chemotherapy,” Pediatric Blood and Cancer 56, no. 7 (2011): 1088-1091.
7.
See Magi et al., supra note 5.
8.
See Bishop et al., supra note 5.
9.
See Diorio et al., supra note 5.
10.
M. A.Cantrell and K.Ruble, “Multidisciplinary Care in Pediatric Oncology,”Journal of Multidisciplinary Healthcare4 (2011): 171-181.
11.
See Paisley et al., supra note 5.
12.
P. S.Hinds, L. L.Oakes, J.Hicks, B.Powell, D. K.Srivastava, S. L.Spunt, J.Harper, J. N.Baker, N. K.West, and W. L.Furman, “‘Trying to be a Good Parent’ as Defined by Interviews with Parents Who Made Phase 1, Terminal Care and Resuscitation Decisions for Their Children,”Journal of Clinical Oncology27, no. 35 (2009): 5979-5985.
13.
J. H.Cheng, L. Y.Chiang, and D. J.Kuo, “Inadvertently Boarding a Pirate Ship: Disease Progression in a Paediatric Patient with Relapsed Metastatic Ewing Sarcoma Receiving Treatment at a Centre for Alternative Therapy in Mexico,”British Medical Journal Case Reports (2017).
14.
K.Kemper and M.Cohen, “Ethics Meet Complementary and Alternative Medicine: New Light on Old Principles,”Contemporary Pediatrics21, 3 (2004): 61-72.
15.
See Bishop et al., supra note 5; Paisley et al., supra note 5.
16.
See Hinds et al., supra note 11.
17.
J. M.Peppercorn, T. J.Smith, P. R.Helft, D. J.Debono, S. R.Berry, D. S.Wollins, D. M.Hayes, J. H.Von Roenn, and L. E.Schnipper, “American Society of Clinical Oncology Statement: Toward Individualized Care for Patients with Advanced Cancer,”Journal of Clinical Oncology29, no. 6 (2011): 755-760.
18.
E.Kodish, “Pediatric Ethics and Early-Phase Childhood Cancer Research: Conflicted Goals and the Prospect of Benefit,”Accountability in Research10, no. 1 (2003): 17-25.
19.
N. E.Kass, R. R.Faden, S. N.Goodman, P.Pronovost, S.Tunis, and T. L.Beauchamp, “The Research-Treatment Distinction: A Problematic Approach for Determining Which Activities Should Have Ethical Oversight,”Hastings Center Report43, no. s1 (2013): S4-S15.
20.
A. R.Jonsen, M.Siegler, and W. J.Winslade, Clinical Ethics: A Practical Approach to Ethical Decisions in Clinical Medicine, 8th Edition (Columbus, Ohio: McGraw Hill Education, 2015): at 1.
21.
E. J.Emanuel, D.Wendler, and C.Grady, “What Makes Clinical Research Ethical?”JAMA283, no. 20 (2000): 2701-2711.
22.
J. D.Lantos, “The ‘Inclusion Benefit’ in Clinical Trials,”Journal of Pediatrics134, no. 2 (1999): 130-131.
23.
See Lantos, supra note 21.
24.
B. A.Sisk, J.DuBois, E.Kodish, J.Wolfe, and C.Feudtner, “Navigating Decisional Discord: The Pediatrician's Role when Child and Parents Disagree,”Pediatrics139, no. 6 (2017): e20170234.
